Scleroderma Lung Study Ii: Comparison Of Therapy With Mycophenolate Mofetil Versus Oral Cyclophosphamide In Patients With Symptomatic Scleroderma Interstitial Lung Disease

被引：0
|
作者：
Tashkin, D. P. [1 ]
Roth, M. D. [1 ]
Furst, D. E. [1 ]
Clements, P. [1 ]
Khanna, D. [2 ]
Volkmann, E. [1 ]
Kalafa, S. [1 ]
Goldin, J. [3 ]
Kim, G. H. J. [3 ]
Arriola, E. [4 ]
Tseng, C. -H. [4 ]
Elashoff, R. E. [4 ]
机构：
[1] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA
[2] Univ Michigan, Sch Med, Ann Arbor, MI USA
[3] David Gefen Sch IMed, Los Angeles, CA USA
[4] David Geffen Sch Med, Los Angeles, CA USA
来源：
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE | 2016年 / 193卷
关键词：
D O I：
暂无
中图分类号：
R4 [临床医学];
学科分类号：
1002 ; 100602 ;
摘要：
A6432
引用
收藏
页数：2
相关论文
共 50 条
  • [41] Long term effects of cyclophosphamide treatment on lung function in scleroderma patients with interstitial lung disease
    Mittoo, Shikha
    Wise, Robert A.
    Wigley, Fredrick
    Hummers, Laura K.
    JOURNAL OF RHEUMATOLOGY, 2008, 35 (06) : 1179 - 1179
  • [42] INTERSTITIAL LUNG DISEASE IN SCLERODERMA PORTUGUESE PATIENTS
    Sousa, S. I.
    Duarte, A.
    Cordeiro, I.
    Teixeira, L.
    Canas da Silva, J.
    Cordeiro, A.
    Santos, M. J.
    ANNALS OF THE RHEUMATIC DISEASES, 2016, 75 : 1122 - 1122
  • [43] Impact of oral cyclophosphamide on health-related quality of life in patients with active scleroderma lung disease - Results from the scleroderma lung study
    Khanna, Dinesh
    Yan, Xiaohong
    Tashkin, Donald P.
    Furst, Daniel E.
    Elashoff, Robert
    Roth, Michael D.
    Silver, Richard
    Strange, Charlie
    Bolster, Marcy
    Seibold, James R.
    Riley, David J.
    Hsu, Vivien M.
    Varga, John
    Schraufnagel, Dean E.
    Theodore, Arthur
    Simms, Robert
    Wise, Robert
    Wigley, Fredrick
    White, Barbara
    Steen, Virginia
    Read, Charles
    Mayes, Maureen
    Parsley, Ed
    Mubarak, Kamal
    Connolly, M. Kari
    Golden, Jeffrey
    Olman, Mitchell
    Fessler, Barri
    Rothfield, Naomi
    Metersky, Mark
    Clements, Philip J.
    ARTHRITIS AND RHEUMATISM, 2007, 56 (05): : 1676 - 1684
  • [44] SCLERODERMA RELATED INTERSTITIAL LUNG DISEASE AND MYCOPHENOLATE : LONG TERM OUTCOMES
    Janardana, R.
    Irodi, A.
    Chebbi, P. P.
    Rv, L.
    Danda, D.
    Mahasampath, G.
    ANNALS OF THE RHEUMATIC DISEASES, 2018, 77 : 123 - 124
  • [45] Effect of mycophenolate sodium in scleroderma-related interstitial lung disease
    Pilar Simeon-Aznar, Carmen
    Fonollosa-Pla, Vicent
    Tolosa-Vilella, Carles
    Selva-O'Callaghan, Albert
    Solans-Laque, Roser
    Vilardell-Tarres, Miquel
    CLINICAL RHEUMATOLOGY, 2011, 30 (11) : 1393 - 1398
  • [46] Effect of mycophenolate sodium in scleroderma-related interstitial lung disease
    Carmen Pilar Simeón-Aznar
    Vicent Fonollosa-Plá
    Carles Tolosa-Vilella
    Albert Selva-O’Callaghan
    Roser Solans-Laqué
    Miquel Vilardell-Tarrés
    Clinical Rheumatology, 2011, 30 : 1393 - 1398
  • [47] Interstitial lung disease: is interstitial lung disease the same as scleroderma lung disease?
    Murray, Lynne A.
    Rubinowitz, Ami
    Herzog, Erica L.
    CURRENT OPINION IN RHEUMATOLOGY, 2012, 24 (06) : 656 - 662
  • [48] Cyclophosphamide monotherapy for scleroderma lung disease
    Brouwer, E
    Bootsma, H
    Bijl, M
    Douma, RW
    Kallenberg, CGM
    ANNALS OF THE RHEUMATIC DISEASES, 2004, 63 : 341 - 342
  • [49] Two-year experience with mycophenolate mofetil in patients with scleroderma lung disease: a case series
    Yilmaz, Neslihan
    Can, Meryem
    Kocakaya, Derya
    Karakurt, Sait
    Yavuz, Sule
    INTERNATIONAL JOURNAL OF RHEUMATIC DISEASES, 2014, 17 (08) : 923 - 928
  • [50] Cyclophosphamide in scleroderma lung disease - Reply
    Tashkin, Donald P.
    Clements, Philip J.
    Roth, Michael D.
    NEW ENGLAND JOURNAL OF MEDICINE, 2006, 355 (11): : 1174 - 1174
12345